<DOC>
	<DOCNO>NCT00918177</DOCNO>
	<brief_summary>The purpose study evaluate blood level profile multiple oral dos AP09004 vs. active control determine safety efficacy Parkinson 's patient .</brief_summary>
	<brief_title>An Evaluation Pharmacokinetics Pharmacodynamics AP09004 Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Subjects age 18 75 year age inclusive ; For early patient : Subject Parkinson 's disease stable response Levodopa ( suffer `` wear '' ) currently treat IRCarbidopa/Levodopa contain 300500mg Levodopa per day 4 dos per day . For group 3 : Subject Parkinson 's disease experience predictable motor fluctuation , end dose `` wearing '' , define patient 's report least two episode daily decline function peak benefit , least 23 hour OFF day discretion PI ( include early morning akinesia ) . Only patient end dose wear least 3 month include . For moderate patient : patient currently treat IRCarbidopa/Levodopa contain 600900mg Levodopa , divide dose , per day . Subject stable current CD/LD dose least 1 month Hoehn Yahr stag IIII If subject take dopamine agonist , dose stable least 1 month Other Parkinson 's disease , subject satisfactory health , assess physical examination , blood test ( biochemistry hematology ) . No abnormality clinical examination blood test opinion Physician responsible compromise safety interfere study procedure . Subjects participate another clinical trial within last 30 day ; Subjects atypical Parkinsonism Subject significant history cardiac , pulmonary , hepatic renal disease condition major complication/illness , opinion physician responsible , contraindicate his/her participation . Subject symptomatic gastroparesis frequent vomit ( least week ) . Subjects history clinically define GERD , peptic ulcer gastrointestinal surgery appendectomy herniotomy , gastrointestinal disorder likely influence drug absorption , history inflammatory bowel disease , irritable bowel syndrome , severe gastrointestinal narrowing , frequent nausea emesis , regardless etiology . Prior gastrointestinal surgery current gastrointestinal condition clinical significance include ulcer , diarrhea , vomit , bleeding , intestinal obstruction inflammatory bowel disease , , opinion physician responsible , contraindicate his/her participation . History drug alcohol abuse . Subject history allergy component dosage form allergy , , opinion physician responsible , contraindicate his/her participation . Subjects suffer psychological disorder opinion physician responsible may interfere full participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>